Marinus’ IV seizure drug faces efficacy questions as Ph3 continues past interim analysis
Marinus Pharmaceuticals is continuing a Phase 3 trial of an intravenous treatment for prolonged seizures past an interim analysis, which suggests …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
